retatrutide case study Significantly Reduces Visceral Fat in Clinical Trials Retatrutide, a GIP, GLP-1 and

Here's the science bit: drugs like Ozempic, WeGovy and Mounjaro work as GLP-1 agonists - essentially, they mimic the effects of our natural GLP-1 production, meaning they can help treat obesity and conditions such as diabetes, and insulin sensitivities such as polycystic ovarian syndrome (PCOS)

Increased activity sustains more weight loss, which amplifies your physical capacity

However, among other effects, it is in part able to suppress nausea, by acting directly on the Area Postrema, (the same part of the brain that we introduced which regulates vomiting in humans) [24] , which is thought to be a contributing factor as to why dual GLP1R/GIPR agonists are able to act synergistically

(3) Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R and Jones R (2025) Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study

Notably, surgical patients achieved greater absolute weight loss yet the GLP-1 cohort demonstrated a comparatively lower incidence of obesity-related cancers